重症COVID-19早期使用肝素治疗性抗凝的回顾性研究
该回顾性观察研究纳入2020年5月1日至2021年9月30日日本一家三级急诊重症医院ICU内需机械通气的重症COVID-19患者198例,按治疗性抗凝启动时机分为早期组(氧疗开始后≤5天,104例,52.5%)和晚期组(>5天,94例,47.5%)。早期组院内死亡率显著低于晚期组(3.8% vs 27.7%,p<0.001),抗凝相关不良事件率更低(1.9% vs 12.8%,p<0.001),无呼吸机天数和无ICU天数更长,ECMO使用率更低。作者结论为晚期给予治疗性剂量抗凝与更差结局显著相关。
要点
- 早期组(氧疗开始后≤5天启动治疗性普通肝素抗凝)院内死亡率为3.8%,晚期组(>5天)为27.7%(p<0.001)。
- 早期组抗凝相关不良事件率为1.9%,晚期组为12.8%(p<0.001)。
- 多因素模型中早期组无呼吸机天数和无ICU天数显著更长,ECMO使用率更低。
- 两组基线特征相似,但本研究为回顾性观察,作者结论为晚期抗凝与更差结局显著相关,不能据此确立因果。
适用人群与场景
- 2020年5月1日至2021年9月30日日本一家三级急诊重症医院ICU内需机械通气的重症COVID-19患者。
诊断标准与关键阈值
- 按治疗性抗凝启动时机分组:氧疗开始后≤5天为早期组,>5天为晚期组。
处置流程与药物剂量
- 治疗性抗凝药物为普通肝素(unfractionated heparin),原文未报告具体剂量、给药途径和频次。
研究设计与关键结果
- 回顾性观察研究,纳入198例需机械通气的重症COVID-19患者,早期组104例(52.5%),晚期组94例(47.5%)。
- 早期组院内死亡率为3.8%,晚期组为27.7%(p<0.001)。
- 早期组抗凝相关不良事件率为1.9%,晚期组为12.8%(p<0.001)。
- 多因素模型中早期组无呼吸机天数和无ICU天数显著更长,ECMO使用率更低。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,重症COVID-19肺炎患者晚期给予治疗性剂量抗凝与更差结局显著相关(较早期给予),但该结论来自回顾性观察,不能据此确立因果关系或给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although several reports recommend the use of systemic anticoagulation therapy in patients with severe coronavirus disease 2019 (COVID-19) pneumonia, appropriate target population and timing of administration are unknown. We assessed association between therapeutic anticoagulation administration with unfractionated heparin and outcomes in patients with severe COVID-19 pneumonia, assuming that anticoagulant administration effects are influenced by therapy timing.
METHODS: This retrospective observational study included severe COVID-19 patients requiring mechanical ventilation in a tertiary emergency critical care hospital intensive care unit (ICU) in Japan from May 1, 2020 to September 30, 2021. All included patients were divided into early and late-phase administration groups based on therapeutic anticoagulant administration timing (≤5 and >5 days, respectively, after commencing oxygen therapy). Primary outcomes (in-hospital mortality and adverse events related to anticoagulation therapy) and secondary outcomes [veno-venous extracorporeal membrane oxygenation (ECMO), ventilator-free days (VFD), and ICU-free days] were compared between groups using univariate and multivariate models.
RESULTS: Of 198 included patients 104 (52.5%) and 94 (47.5%) were in early-phase and late-phase administration groups, respectively. Although background characteristics were similar between the groups, the early-phase administration group had a significantly lower in-hospital mortality rate (3.8% vs. 27.7%; p < 0.001), lower adverse event rates (1.9% vs. 12.8%; p < 0.001), significantly longer VFD and ICU-free days, and lower ECMO rates, than the late-phase administration group, in the multivariate model.
CONCLUSIONS: Late administration of therapeutic-dose anticoagulation in patients with severe COVID-19 pneumonia was significantly associated with worse outcomes than early administration.
参考来源
- Takayama W, Endo A, Otomo Y, et al. Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective study. Am J Emerg Med. 2022. PMID: 35640454. doi:10.1016/j.ajem.2022.05.031
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。